One Thousand Patients With Primary Myelofibrosis: The Mayo Clinic Experience
2012/01/01 by Ayalew Tefferi, Terra L. Lasho, Thitina Jimma +9 · 27 citations
Medicine · #Myeloproliferative Neoplasms: Diagnosis and Treatment #Multiple Myeloma Research and Treatments #Acute Myeloid Leukemia Research
paper · pdf · doi:10.1016/j.mayocp.2011.11.001
Cited by
- 3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups
- Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management
- Ruxolitinib for myelofibrosis--an update of its clinical effects. [europepmc]
- Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. [europepmc]
- Bone marrow fibrosis as a feature of systemic lupus erythematosus: a case report and literature review. [europepmc]
- Effects of ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis from COMFORT-I. [europepmc]
- Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis. [europepmc]
- The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. [europepmc]
- Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis. [europepmc]
- Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. [europepmc]
- Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. [europepmc]
- Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents. [europepmc]
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. [europepmc]
- Efficacy of ALK5 inhibition in myelofibrosis. [europepmc]
- Allogeneic Stem Cell Transplantation in Myelofibrosis. [europepmc]
- Development of a harmonized patient-reported outcome questionnaire to assess myelofibrosis symptoms in clinical trials. [europepmc]
- Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. [europepmc]
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. [europepmc]
- Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis. [europepmc]
- EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. [europepmc]
- MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen. [europepmc]
- Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies. [europepmc]
- Management of myelofibrosis after ruxolitinib failure. [europepmc]
- MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria. [europepmc]
- Momelotinib: an emerging treatment for myelofibrosis patients with anemia. [europepmc]
- Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. [europepmc]
- One thousand patients with essential thrombocythemia: the Mayo Clinic experience. [europepmc]